REDUCED RISK OF PROSTATE CANCER IN INFERTILE MEN COMPARED TO MEN WITH PROVEN FERTILITY: A NESTED CASE- CONTROL STUDY

Abstract In this paper, we describe the Prognostic Factors for Mortality in Prostate Cancer (ProMort) study and use it to demonstrate how the weighted likelihood method can be used in nested case-control studies to estimate both relative and absolute risks in the competing-risks setting. ProMort is a case-control study nested within the National Prostate Cancer Register (NPCR) of Sweden, comprising 1,710 men diagnosed with low- or intermediate-risk prostate cancer between 1998 and 2011 who died from prostate cancer (cases) and 1,710 matched controls. Cause-specific hazard ratios and cumulative incidence functions (CIFs) for prostate cancer death were estimated in ProMort using weighted flexible parametric models and compared with the corresponding estimates from the NPCR cohort. We further drew 1,500 random nested case-control subsamples of the NPCR cohort and quantified the bias in the hazard ratio and CIF estimates. Finally, we compared the ProMort estimates with those obtained by augmenting competing-risks cases and by augmenting both competing-risks cases and controls. The hazard ratios for prostate cancer death estimated in ProMort were comparable to those in the NPCR. The hazard ratios for dying from other causes were biased, which introduced bias in the CIFs estimated in the competing-risks setting. When augmenting both competing-risks cases and controls, the bias was reduced.

Download Full-text

UP-1.089: Prostate Cancer Risk in Relation to Serum Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3: A Nested Case-Control Study in Japan

Urology ◽

10.1016/j.urology.2009.07.536 ◽

2009 ◽

Vol 74 (4) ◽

pp. S197-S198

Author(s):

K. Mikami ◽

K. Ozasa ◽

M. Nakao ◽

T. Miki ◽

K. Hayashi ◽

...

Keyword(s):

Prostate Cancer ◽

Case Control Study ◽

Serum Insulin ◽

Prostate Cancer Risk ◽

Case Control ◽

Igf I ◽

Igf Binding ◽

Igf Binding Protein ◽

Nested Case Control ◽

Control Study

Download Full-text

Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study

Journal of Clinical Medicine ◽

10.3390/jcm8122150 ◽

2019 ◽

Vol 8 (12) ◽

pp. 2150 ◽

Cited By ~ 2

Author(s):

Sara Rodríguez-Martín ◽

Francisco J. de Abajo ◽

Miguel Gil ◽

Diana González-Bermejo ◽

Antonio Rodríguez-Miguel ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Case Control Study ◽

Serum Urate ◽

Case Control ◽

Dose Effect ◽

Duration Of Treatment ◽

Nested Case Control ◽

Control Study ◽

Reduced Risk

Objectives: To test the hypothesis that allopurinol reduces the risk of acute myocardial infarction (AMI) in hyperuricemic patients and to assess whether the effect is dependent on dose, duration and serum uric acid (SUA) level attained after treatment. Methods: Nested case-control study over the period 2002–2015. From a cohort of patients aged 40–99 years old, we identified incident AMI cases and randomly selected five controls per case, matched for exact age, sex and index date. Adjusted odds ratios (AOR) and 95% CI were computed through unconditional logistic regression. Only new users of allopurinol were considered. Results: A total of 4697 AMI cases and 18,919 controls were included. Allopurinol use was associated with a reduced risk of AMI mainly driven by duration of treatment (AOR ≥180 days = 0.71; 95% CI: 0.60–0.84). Among long-term users (≥180 days), the reduced risk was only observed when the SUA level attained was below 7 mg/dL (AOR<6 mg/dL = 0.64; 95% CI: 0.49–0.82; AOR6–7mg/dL = 0.64; 95%CI:0.48-0.84); AOR>7mg/dL = 1.04; 95% CI: 0.75–1.46; p for trend = 0.001). A dose-effect was observed but faded out once adjusted for the SUA level attained. The reduced risk of AMI occurred in both patients with gout and patients with asymptomatic hyperuricemia. Conclusions: The results confirm a cardioprotective effect of allopurinol which is strongly dependent on duration and SUA level attained after treatment.

Download Full-text